JAMA Network
About The Study: Discrepancies were observed between labeled and measured concentrations of nicotine analogues in e-cigarettes and e-cigarette liquids marketed as nicotine replacements and exempt from FDA's regulatory purview. Such discrepancies may lead to uncertainty about user exposure. When coupled with the largely unknown acute and chronic inhalation hazards and addictive potential of nicotine analogues, assessing product risk based on exposure becomes challenging from a clinical and regulatory standpoint. With e-cigarettes increasingly considered for smoking cessation, the advent of nicotine analogue–containing products with unknown health risks raises concern.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
